Astrazeneca Share News (AZN)

(Alliance News) - Avacta Group PLC on Tuesday saw its shares rise, as it said new data demonstrates a favourable delivery profile and advantages of its preCision platform when compared to a marketed antibody drug conjugate.

Shares in the London-based life sciences company were up 6.4% at 60.10 pence on Tuesday morning in London. The stock has risen by 47% in the last 12 months.

Avacta's preCision platform is a proprietary payload delivery system designed to concentrate highly potent payloads in the tumour microenvironment while sparing normal tissues.

The company explained that its data analysis compared preCision FAP-cleavable payload delivery with Enhertu, a protease-cleavable linker ADC approved for breast and gastric cancer indications.

Enhertu is manufactured by Daiichi Sankyo Co Ltd, and is being jointly developed and commercialised in collaboration with AstraZeneca PLC.

Avacta said its analysis demonstrated three key pharmacokinetic advantages, noting that AVA6103 results in more rapid drug penetration into the tumour. The company said it also observed higher tumour concentration as well as greater tumour selectivity.

The company expects to begin the phase one clinical trial of its FAP-Exd, AVA6103, programme in the first quarter of this year.

"Our analysis demonstrates three potential advantages of our proprietary preCision delivery mechanism when compared to the marketed ADC, Enhertu: more rapid drug penetration into the tumour, a one log higher absolute maximum drug concentration in the tumour and the Tumor Selectivity Index (a critical safety and effectiveness measure) being nearly three-fold higher," said Chief Executive Christina Coughlin.

"This data analysis supports our belief that our preCision payload delivery mechanism has many key advantages over the ADC mechanism, currently one of the most successful drug classes in oncology.

"We believe the observations in this dataset have significantly increased the probability of success with FAP-Exd, given both the ability of FAP-Exd to deliver more payload selectively to the tumour in the preclinical setting and success of Enhertu in the clinic. We look forward to the start of the clinical trial."

By Christopher Ward, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2026 Alliance News Ltd. All Rights Reserved.